Repros Therapeutics (NASDAQ:RPRX), Enzymotec Ltd. (NASDAQ:ENZY) and Covisint Corp. (NASDAQ:COVS) are making big gains this Thursday. Voltari Corp. (NASDAQ:VLTC), Xenon Pharmaceuticals Inc. (NASDAQ:XENE) and Scorpio Bulkers Inc. (NYSE:SALT) are posting losses.
Sign up for our free newsletter
Gates Capital Management's ECF Value Funds have a fantastic track record. The funds (full-name Excess Cash Flow Value Funds), which invest in an event-driven equity and credit strategy, have produced a 12.6% annualised return over the past 26 years. The funds added 7.7% overall in the second half of 2022, outperforming the 3.4% return for Read More
Repros Therapeutics Climbs on FDA Application Approval
[drizzle]
Repros Therapeutics climbed +9.31% early in the day after announcing yesterday that the FDA has accepted its new drug application. Farallon Capital has a small stake in the biotech company.
Enzymotec Ltd. rallied +7.34% this morning, though year-to-date its performance remains flat. John Paulson owns 4.24 million ENZY shares – 19.27% of the company.
Covisint Corp. gained +7.14% this Thursday, though the stock is still down more than -20% year-to-date. Short interest in COVS is on the rise, and it hit a new 52-week low last month. This is another Farallon Capital pick.
Voltari Corp. Dips
Voltari Corp. dipped -7.6% this morning, though it’s still up an incredible +182.5% over the past five days. The explanation: Carl Icahn’s disclosure of what appears to be an activist stake in the firm.
Xenon Pharmaceuticals tumbled -4.26% and is down -15% YTD. Wilbur Ross has a stake in the company.
Scorpio Bulkers Inc. fell -4.07% early in the day, though it’s still up about +7% in 2015. As of the end of the fourth quarter of last year, Marc Lasry holds 16.53 million SALT shares. The company has a 3.01% in his public equity portfolio.
[/drizzle]